(Total Views: 454)
Posted On: 10/15/2022 2:49:51 AM
Post# of 36541
1,5 Millionen? USD.?
They've got to be kidding. Mr. Delosi had keyed out plans (during that May '21 CC) to roll out Excellegen to the market with was supposed to generate double digit millions of dollars in revenues within 6 months of the launch.
So here is my question: if this remains the only big, are these assets definitely be sold for that measly 1,5 mill.? I sure hope not.
Another one thing I want to mention here in terms of remaining assets that do /should have considerable value is Oral-lyn. Back in 2005 Anna G. estimated the total Diabetes market in the US to be 2 billion dollars and she wanted to get a 10% share of that market back then. So I guess the diabetes problem all over the world has grown significantly and thus there shield still be a market for Oral-lyn. It seems as if the reformulation was completed, and all it takes is (at max a full) phase 3 clinical trial again, before it can be FDA approved.
They've got to be kidding. Mr. Delosi had keyed out plans (during that May '21 CC) to roll out Excellegen to the market with was supposed to generate double digit millions of dollars in revenues within 6 months of the launch.
So here is my question: if this remains the only big, are these assets definitely be sold for that measly 1,5 mill.? I sure hope not.
Another one thing I want to mention here in terms of remaining assets that do /should have considerable value is Oral-lyn. Back in 2005 Anna G. estimated the total Diabetes market in the US to be 2 billion dollars and she wanted to get a 10% share of that market back then. So I guess the diabetes problem all over the world has grown significantly and thus there shield still be a market for Oral-lyn. It seems as if the reformulation was completed, and all it takes is (at max a full) phase 3 clinical trial again, before it can be FDA approved.
(0)
(0)Scroll down for more posts ▼
